TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16213237

Group type: EXPERIMENTAL
Intervention: Home-based physical therapy (PT) group (n=13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 25
Study: 11908582

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) of the hip
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no history of hip joint or rheumatic disease)
Number of subjects: 24
Study: 10100994

Group type: EXPERIMENTAL
Intervention: Intrpulmonary instillation of 2.6 microm-diameter iron oxide particles
Number of subjects: 0
Study: 7762370

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 60
Study: 2218196

Group type: EXPERIMENTAL
Intervention: Matched design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline smoking quit rates
Number of subjects: 0
Study: 7010522

Group type: EXPERIMENTAL
Intervention: N-acetyl-5-aminosalicylic acid (Ac-5-ASA) retention enemas
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dummy enemas (placebo)
Number of subjects: 40
Study: 31532959

Group type: EXPERIMENTAL
Intervention: Polypill (atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 303
Study: 29223666

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 126
Study: 27552065

Group type: EXPERIMENTAL
Intervention: Yoga practice for 8 weeks
Number of subjects: 15
Study: 23570583

Group type: EXPERIMENTAL
Intervention: Major Depressive Episodes (MDEs)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Partial or full remission
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: No or active substance abuse
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Current MDE
Number of subjects: 137
Study: 21837534

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily plus phloroglucinol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg plus phloroglucinol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Phloroglucinol 240 mg daily (Control Group)
Number of subjects: 150
Study: 19671145

Group type: EXPERIMENTAL
Intervention: Exercise therapy (1-hour session, 4 times a week for 10 weeks) plus pharmacological therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pharmacological therapy only
Number of subjects: 24
Study: 17067857

Group type: EXPERIMENTAL
Intervention: Re-randomization for optimal dosing
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Re-randomization for optimal dose-scheduling
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Re-randomization for salvage therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Direct comparison trials
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Standard efficacy trials
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment trials
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Patient loss from period 1 to period 2
Number of subjects: 65
Study: 15745869

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 65
Study: 11737692

Group type: EXPERIMENTAL
Intervention: Griseofulvin (20 mg/kg/day for 6 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Terbinafine (> 40 kg: 250 mg; 20-40 kg: 125 mg; < 20 kg: 62.5 mg for 2-3 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Itraconazole (5 mg/kg/day for 2-3 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg/day for 2-3 weeks)
Number of subjects: 200
Study: 9415509

Group type: EXPERIMENTAL
Intervention: Lamotrigine (400 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8236387

Group type: EXPERIMENTAL
Intervention: Community involvement in Aedes aegypti control programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated neighborhoods
Number of subjects: 0
Study: 3631772

Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled with a tube spacer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Terbutaline inhaled without a tube spacer (conventional inhaler)
Number of subjects: 18
Study: 31076466

Group type: EXPERIMENTAL
Intervention: Online acceptance and commitment therapy (ACT) intervention, 8 sessions over 8 weeks
Number of subjects: 192

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 192
Study: 27618363

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 6975

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6975
Study: 25753087

Group type: EXPERIMENTAL
Intervention: Transdermal Fentanyl patches
Number of subjects: 196

Group type: COMPARATOR
Intervention: Patient Controlled Analgesia (PCA)
Number of subjects: 196
Study: 24089671

Group type: EXPERIMENTAL
Intervention: HDM200
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HDM140 + TMI 8 Gy
Number of subjects: 9
Study: 21297553

Group type: EXPERIMENTAL
Intervention: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS) (2880 mg/day for days 0-14, 2160 mg/day for days 15-42, followed by 1440 mg/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS) (1440 mg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both ID and SD regimens
Number of subjects: 128
Study: 19805674

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 30 mg IV three times weekly for up to 3 months and pentostatin 4 mg/m2 IV weekly for 4 weeks followed by alternate weekly administration for up to 6 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alemtuzumab and pentostatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics including antiviral, antifungal, and antibacterial agents
Number of subjects: 24
Study: 16939066

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS, myfortic) 720 mg b.i.d. with cyclosporine microemulsion and corticosteroids
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS, myfortic)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 297
Study: 15246599

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 11374602

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, 1 x 10(6) KIU before reperfusion; n = 24)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 0.5 x 10(6) KIU/h; n = 21)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 67
Study: 11823998

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 930

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 930
Study: 1414239

Group type: EXPERIMENTAL
Intervention: Oxiracetam (800 mg tablet), twice daily for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 65
Study: 3919076

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30316960

Group type: EXPERIMENTAL
Intervention: High-intensity home-based respiratory muscle training (40 minutes, 7 days/week for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (sham intervention of similar dose)
Number of subjects: 38
Study: 29386172

Group type: EXPERIMENTAL
Intervention: Remote Collaborative Depression Care (RCDC), N=65, 3-month treatment with continuous remote supervision by psychiatrists through shared electronic health records (SEHR) and phone monitoring.
Number of subjects: 143

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC), N=78, provided by clinicians following clinical guidelines.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both groups (RCDC and EUC).
Number of subjects: 143
Study: 28239635

Group type: EXPERIMENTAL
Intervention: Work, Family and Health Study intervention aimed at reducing work-family conflict through interactive sessions and training in family-supportive supervision.
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Work, Family and Health Study intervention
Number of subjects: 1706
Study: 24210149

Group type: EXPERIMENTAL
Intervention: Absorbable braided sutures (Vycril; Ethicon)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nonabsorbable monofilament sutures (Prolene; Ethicon)
Number of subjects: 200
Study: 22464674

Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate (heat‐killed Escherichia coli and Enterococcus faecalis) from week 5 until the end of month 7
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate
Number of subjects: 606
Study: 20383345

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 14 days
Number of subjects: 211

Group type: COMPARATOR
Intervention: Doxycycline 100 mg orally twice daily for 21 days
Number of subjects: 211
Study: 18977834

Group type: EXPERIMENTAL
Intervention: Distal radius vascularised bone graft
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iliac crest non‐vascularised bone graft
Number of subjects: 80
Study: 15750458

Group type: EXPERIMENTAL
Intervention: Oseltamivir (2 mg/kg)
Number of subjects: 179
Study: 12427146

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 1200 mg one hour before angiography and a second dose 3 hours after; IV hydration
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo; IV hydration
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in patients with diabetes mellitus
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo in patients with diabetes mellitus
Number of subjects: 79
Study: 10520903

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 43
Study: 8719696

Group type: EXPERIMENTAL
Intervention: Corticosteroids (intervention for acute demyelinating optic neuritis)
Number of subjects: 488
Study: 1399301

Group type: EXPERIMENTAL
Intervention: wide spectrum intravenous antibiotics and suction and debridement
Number of subjects: 48
Study: 3160322

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (20 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefoxitin sodium (30 mg/kg)
Number of subjects: 40
Study: 29549483

Group type: EXPERIMENTAL
Intervention: Transgluteal group (n=80; treated in the supine position using a transgluteal approach)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Prone group (n=80; treated in the conventional prone position)
Number of subjects: 160
Study: 27754427

Group type: EXPERIMENTAL
Intervention: Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23488280

Group type: EXPERIMENTAL
Intervention: Testosterone deficiency syndrome (TDS) in MS patients
Number of subjects: 77

Group type: COMPARATOR
Intervention: Testosterone deficiency syndrome (TDS) in obese patients without MS
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MS(+) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MS(+) TDS(+) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Correlation between TT and body weight in MS(+) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Correlation between SHBG and waist circumference in MS(+) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Correlation between SHBG and body weight in MS(+) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Correlation between SHBG and age in MS(+) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fasting lipid levels, fasting blood glucose, CRP, Fb, BP
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: TT, fT, SHBG and IIEF-5, AMS score
Number of subjects: 77
Study: 20393809

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 40
Study: 19951404

Group type: EXPERIMENTAL
Intervention: Integrated, multidisciplinary care involving a dermatologist, care manager, specialized nurse, and clinical occupational physician.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care by a dermatologist.
Number of subjects: 0
Study: 18020888

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: No hormonal replacement therapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Female population aged 40-44 years
Number of subjects: 500
Study: 15516696

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg daily)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Telmisartan and Enalapril
Number of subjects: 250
Study: 11212625

Group type: EXPERIMENTAL
Intervention: Conditions adhering to the Morton-Massaro law (MML)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural stimuli analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feed-forward and interactive models
Number of subjects: 0
Study: 9516894

Group type: EXPERIMENTAL
Intervention: Montelukast 100 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Montelukast 50 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8458257

Group type: EXPERIMENTAL
Intervention: Trimebutine (200 mg/day per os) for one month
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 24
Study: 3802303

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg/die/p.o.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ranitidine 300 mg/die/p.o.
Number of subjects: 38
Study: 29948994

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 150

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 150
Study: 26883644

Group type: EXPERIMENTAL
Intervention: COMPASS consultation intervention
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Stronger parent-teacher alliance
Number of subjects: 79
Study: 25052238

Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg 3 times daily for 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo 10 mg 3 times daily for 5 days
Number of subjects: 30
Study: 21926427

Group type: EXPERIMENTAL
Intervention: CYP2D6 IM/PM genotypic category
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CYP2C19*17 allele (UM phenotype)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CYP2C19 PM phenotype
Number of subjects: 196
Study: 20395869

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg every day for 4 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice a day for 4 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg every day + Raltegravir 400 mg twice a day for 4 days
Number of subjects: 24
Study: 18315579

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1 g o.d. for 3 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1 g o.d. for 1 month
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 41
Study: 15737906

Group type: EXPERIMENTAL
Intervention: Urethral dose <150% minimum peripheral dose (mPD)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Urethral dose 150% minimum peripheral dose (mPD)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Isotope used in brachytherapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Preimplant International Prostate Symptom Score (I‐PSS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: D(90)
Number of subjects: 108
Study: 12463428

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 69

Group type: COMPARATOR
Intervention: 0.25% racemic bupivacaine
Number of subjects: 69
Study: 10327193

Group type: EXPERIMENTAL
Intervention: MDV2 double-immunostaining method
Number of subjects: 0
Study: 7549303

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) 150 U/kg three times per week given sc
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 2027118

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7004470

Group type: EXPERIMENTAL
Intervention: Propranolol 0.15 mg per kg body weight i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no propranolol)
Number of subjects: 0
Study: 31454045

Group type: EXPERIMENTAL
Intervention: Tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Single transplant with carboplatin/etoposide/melphalan (n = 179)
Number of subjects: 355
Study: 28303328

Group type: EXPERIMENTAL
Intervention: Palmitoyl-KVK-L-ascorbic acid cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palmitoyl-KVK-L-ascorbic acid (20 μg/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 25818278

Group type: EXPERIMENTAL
Intervention: Exercise in a contextually enhanced environment for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise in a standard environment for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study: 23873905

Group type: EXPERIMENTAL
Intervention: Laser-assisted (LA) group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Free-hand group
Number of subjects: 82
Study: 21537051

Group type: EXPERIMENTAL
Intervention: Combination vitamin E (800 U), soy (40 g), and selenium (200 μg)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 19610264

Group type: EXPERIMENTAL
Intervention: Fined wines containing egg albumin, lysozyme, milk casein, fish gelatin, or isinglass
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unfined wines
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fined and unfined wines
Number of subjects: 14
Study: 17578197

Group type: EXPERIMENTAL
Intervention: Setegis (terazosin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with alpha-adrenoblockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with antibacterial drugs
Number of subjects: 0
Study: 15152897

Group type: EXPERIMENTAL
Intervention: sustained-release melatonin 2 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: zopiclone 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 11146789

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 4 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9520629

Group type: EXPERIMENTAL
Intervention: Endurance training and heat acclimation (8 weeks training followed by 6 days acclimation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heat acclimation (6 or 12 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Endurance training and heat acclimation
Number of subjects: 24
Study: 8005275

Group type: EXPERIMENTAL
Intervention: Progesterone (P) 50 mg/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Progesterone (P) 50 mg/d + Estrogen (E2) valerate 2 mg/d
Number of subjects: 100
Study: 2510272

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.d.
Number of subjects: 257

Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.d.
Number of subjects: 257
Study: 790546

Group type: EXPERIMENTAL
Intervention: 300 mg/day of ketoprofen
Number of subjects: 50

Group type: COMPARATOR
Intervention: 600 mg/day of phenylbutazone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both drugs (ketoprofen and phenylbutazone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ketoprofen
Number of subjects: 50

Group type: COMPARATOR
Intervention: phenylbutazone
Number of subjects: 50
Study: 31491602

Group type: EXPERIMENTAL
Intervention: ECG metrics analysis in ACS patients
Number of subjects: 4516

Group type: EXPERIMENTAL
Intervention: Radial approach and bivalirudin treatment
Number of subjects: 4516
Study: 27878824

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)-based approach
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard care approach
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 254
Study: 25726153

Group type: EXPERIMENTAL
Intervention: Student Assistance Programme
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention assessment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention clarification
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intervention responsibility
Number of subjects: 15
Study: 23320655

Group type: EXPERIMENTAL
Intervention: Collaborative care management for dementia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 20637053

Group type: EXPERIMENTAL
Intervention: 1,3-β-d-glucan-containing nutritional supplement
Number of subjects: 6
Study: 18974448

Group type: EXPERIMENTAL
Intervention: Unipedal standing therapy (3 times a day for an unspecified duration)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Unipedal standing therapy
Number of subjects: 86
Study: 16550299

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg weekly
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no ALN, receiving calcium and calcitriol)
Number of subjects: 98